Sagimet Biosciences Announces U.S. Phase 3 Trials for Acne Drug Denifanstat
Sagimet Biosciences (SGMT) shares surged 45.2% after announcing plans to initiate Phase 3 trials for its acne drug denifanstat in the U.S., following successful Phase 3 results in China. The move is expected to support the company's growth, despite upcoming share dilution from fundraising efforts.
Tickers: $SGMT
Topics: acne treatment biopharma clinical trials drug development stock price movement